{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:52:14Z","timestamp":1781711534080,"version":"3.54.5"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pharmacogenetics (PGx) is increasingly recognized as an important component of personalized medicine. In kidney transplantation, where immunosuppressive therapies and comedications often have narrow therapeutic index, preemptive PGx could complement therapeutic drug monitoring to improve individualized care. This study aimed to investigate the value of implementing PGx testing in the pretransplant assessment of renal transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This single-center retrospective study included 110 adult patients who underwent a pretransplant PGx assessment between January 1, 2022, and June 30, 2023. The analysis focused on 16 pharmacogenes shared between the local routine PGx panel and the publicly available ClinPGx guideline support interface, with some genes analyzed using hotspot-only coverage. Medication lists were extracted at 2 time points: pretransplant and post-transplant (or last follow-up for patients on waiting list). Theoretical actionability was defined as the presence of at least 1 actionable genotype, and effective actionability as at least 1 actionable gene\u2013drug pair according to international guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Theoretical actionability was observed in 109 of 110 patients (99%). Effective actionability concerned 29 of 110 patients (26%) at the pretransplant assessment and 19 of 41 (46%) at the post-transplant stage. The most frequent actionable gene\u2013drug pairs at the latter stage included\n                      <jats:italic toggle=\"yes\">CYP2C19-<\/jats:italic>\n                      proton pump inhibitors (38%),\n                      <jats:italic toggle=\"yes\">CYP3A5<\/jats:italic>\n                      -tacrolimus (25%),\n                      <jats:italic toggle=\"yes\">SLCO1B1-<\/jats:italic>\n                      statins (13%),\n                      <jats:italic toggle=\"yes\">CYP2D6-tramadol<\/jats:italic>\n                      (8%), and\n                      <jats:italic toggle=\"yes\">ABCG2<\/jats:italic>\n                      -allopurinol (8%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Preemptive PGx embedded in the pretransplant evaluation identifies clinically relevant gene\u2013drug interactions. In combination with therapeutic drug monitoring, this approach has the potential to optimize immunosuppressive drugs initiation and support pharmacological management in kidney transplantation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001485","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:01:12Z","timestamp":1781708472000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Preemptive Pharmacogenetics in Renal Transplantation: A Real-World Assessment of Pharmacogenetic Actionability"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1764-1007","authenticated-orcid":false,"given":"Dorian","family":"Chastagner","sequence":"first","affiliation":[{"name":"Pharmacology & Transplantation, Inserm U 1248, Limoges, France;"},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Arnion","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, Inserm U 1248, Limoges, France;"},{"name":"Faculties of Medicine and Pharmacy, Univ Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Monchaud","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, Inserm U 1248, Limoges, France;"},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"R\u00e9rolle","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Transplantation, CHU Limoges, Limoges, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Danthu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Transplantation, CHU Limoges, Limoges, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatouma","family":"Tour\u00e9","sequence":"additional","affiliation":[{"name":"Faculties of Medicine and Pharmacy, Univ Limoges, Limoges, France."},{"name":"Department of Nephrology, Dialysis and Transplantation, CHU Limoges, Limoges, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8460-903X","authenticated-orcid":false,"given":"Nicolas","family":"Picard","sequence":"additional","affiliation":[{"name":"Pharmacology & Transplantation, Inserm U 1248, Limoges, France;"},{"name":"Department of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France;"},{"name":"Faculties of Medicine and Pharmacy, Univ Limoges, Limoges, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"R1-20260617","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jmoldx.2016.01.003","article-title":"Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing, a customized CYP2D6 genotyping cascade","volume":"18","author":"Ji","year":"2016","journal-title":"J Mol Diagn."},{"key":"R2-20260617","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/cpt.2122","article-title":"Pharmacogenetics at scale: an analysis of the UK biobank","volume":"109","author":"McInnes","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"R3-20260617","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41436-018-0337-5","article-title":"Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions","volume":"21","author":"Reisberg","year":"2019","journal-title":"Genet Med."},{"key":"R4-20260617","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","author":"Swen","year":"2023","journal-title":"Lancet"},{"key":"R5-20260617","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cpt.3702","article-title":"Prevalence of actionable pharmacogenetic genotype frequencies, cautionary medication use, and polypharmacy in community-dwelling older adults","volume":"118","author":"Bousman","year":"2025","journal-title":"Clin Pharmacol Ther."},{"key":"R6-20260617","doi-asserted-by":"crossref","first-page":"10301","DOI":"10.3390\/ijms241210301","article-title":"Current status regarding immunosuppressive treatment in patients after renal transplantation","volume":"24","author":"Szumilas","year":"2023","journal-title":"Int J Mol Sci."},{"key":"R7-20260617","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MNH.0000000000000065","article-title":"Role of pharmacogenomics in dialysis and transplantation","volume":"23","author":"Birdwell","year":"2014","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"R8-20260617","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2010.320","article-title":"Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"R9-20260617","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4097\/kja.d.18.00217","article-title":"Designing the ideal perioperative pain management plan starts with multimodal analgesia","volume":"71","author":"Schwenk","year":"2018","journal-title":"Korean J Anesthesiol."},{"key":"R10-20260617","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med."},{"key":"R11-20260617","doi-asserted-by":"crossref","first-page":"1523399","DOI":"10.3389\/fphar.2025.1523399","article-title":"Association between CYP2C19 polymorphism and proton pump inhibitors adverse drug reactions: a narrative review","volume":"16","author":"Ibrahim","year":"2025","journal-title":"Front Pharmacol."},{"key":"R13-20260617","doi-asserted-by":"crossref","first-page":"1189976","DOI":"10.3389\/fphar.2023.1189976","article-title":"Pharmacogenomics in practice: a review and implementation guide","volume":"14","author":"Kabbani","year":"2023","journal-title":"Front Pharmacol."},{"key":"R14-20260617","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41525-025-00508-1","article-title":"Geno4ME study: implementation of whole genome sequencing for population screening in a large healthcare system","volume":"10","author":"Lucas Beckett","year":"2025","journal-title":"NPJ Genom Med."},{"key":"R15-20260617","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2215\/CJN.02730218","article-title":"Clinical pharmacogenomics: applications in nephrology","volume":"13","author":"Adams","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"key":"R16-20260617","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ekir.2022.12.007","article-title":"Exome-first strategy in adult patients with CKD: a cohort study","volume":"8","author":"Doreille","year":"2023","journal-title":"Kidney Int Rep."},{"key":"R17-20260617","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/cpt.3458","article-title":"Value of pharmacogenetic testing assessed with real-world drug utilization and genotype data","volume":"117","author":"Litonius","year":"2025","journal-title":"Clin Pharmacol Ther."},{"key":"R18-20260617","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.therap.2020.06.004","article-title":"Synth\u00e8se des recommandations de l'International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) sur le suivi th\u00e9rapeutique pharmacologique du tacrolimus","volume":"75","author":"Lemaitre","year":"2020","journal-title":"Therapie"},{"key":"R19-20260617","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/ijms26051960","article-title":"Trends in precision medicine and pharmacogenetics as an adjuvant in establishing a correct immunosuppressive therapy for kidney transplant: an up-to-date historical overview","volume":"26","author":"Belardi","year":"2025","journal-title":"Int J Mol Sci."},{"key":"R20-20260617","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41397-025-00365-2","article-title":"Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment of Slovenian patients undergoing kidney transplantation in the U-PGx PREPARE study","volume":"25","author":"Fragoulakis","year":"2025","journal-title":"Pharmacogenomics J."},{"key":"R21-20260617","doi-asserted-by":"crossref","first-page":"711943","DOI":"10.3389\/fgene.2021.711943","article-title":"CYP3A4\u221722 genotyping in clinical practice: ready for implementation?","volume":"12","author":"Mulder","year":"2021","journal-title":"Front Genet."},{"key":"R22-20260617","doi-asserted-by":"crossref","first-page":"100230","DOI":"10.1016\/j.crphar.2025.100230","article-title":"Pharmacogenetics association with long-term clinical evolution in a kidney transplant patients cohort","volume":"9","author":"Sendra","year":"2025","journal-title":"Curr Res Pharmacol Drug Discov."},{"key":"R23-20260617","first-page":"32","article-title":"Implementation of a renal precision medicine program: clinician attitudes and acceptance","volume":"10","author":"Spiech","year":"2020","journal-title":"Life (Basel)"},{"key":"R24-20260617","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cpt.2711","article-title":"Pharmacogenomic clinical decision support: a scoping review","volume":"113","author":"Smith","year":"2023","journal-title":"Clin Pharmacol Ther."},{"key":"R25-20260617","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/cpt.3736","article-title":"Progress in pharmacogenomics implementation in the United States: barrier erosion and remaining challenges","volume":"118","author":"Smith","year":"2025","journal-title":"Clin Pharmacol Ther."},{"key":"R26-20260617","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3343\/alm.2024.0652","article-title":"Pharmacogenomic testing in the clinical laboratory: historical progress and future opportunities","volume":"45","author":"Moyer","year":"2025","journal-title":"Ann Lab Med."},{"key":"R27-20260617","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/pharmacy11050144","article-title":"The critical role of pharmacists in the clinical delivery of pharmacogenetics in the U.S","volume":"11","author":"Haga","year":"2023","journal-title":"Pharmacy"},{"key":"R28-20260617","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/pharmacy11020069","article-title":"The effect of genotyping on the number of pharmacotherapeutic gene\u2013drug interventions in chronic kidney disease patients","volume":"11","author":"Kerskes","year":"2023","journal-title":"Pharmacy"},{"key":"R29-20260617","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3390\/jpm11111123","article-title":"A cost-consequence analysis of preemptive SLCO1B1 testing for statin myopathy risk compared to usual care","volume":"11","author":"Brunette","year":"2021","journal-title":"J Pers Med."},{"key":"R30-20260617","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41397-025-00376-z","article-title":"Analyzing pharmacogenetics cost effectiveness and savings across common health conditions in the United States","volume":"25","author":"Patel","year":"2025","journal-title":"Pharmacogenomics J."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:01:17Z","timestamp":1781708477000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001485","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"2025-11-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}